title: [Anti-VEGF-agents in treatment of neovascular glaucoma].
abstract: Neovascular glaucoma (NVG) is one of the most severe form of refractory glaucoma. Vascular endothelial growth factor (VEGF) is one of the strongest promoters of angiogenesis and was found to be the main neovascularization regulator. The use of anti-VEGF-agents is a rational option because in the majority of cases it allows to reach disappearance or reduction of neovascularization, that significantly reduces the risk of complications in following surgery or laser treatment of NVG.
authors.forename: M M
authors.initials: MM
authors.lastname: Bikbov
authors.forename: A É
authors.initials: AÉ
authors.lastname: Babushkin
authors.forename: O I
authors.initials: OI
authors.lastname: Orenburkina
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D018463:Filtering Surgery / Q000379:methods*; D015355:Glaucoma, Neovascular / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D056965:Injections, Intraocular; D009389:Neovascularization, Pathologic / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D011300:Preoperative Care / Q000379:methods*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab